Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today told DirectorsTalk that clinical trial supplies in the form of sterile ampoules of iclaprim have been manufactured. Following Quality Assurance release, these supplies will be shipped to clinical trial sites. These activities enable Motif to remain on target to complete the two, previously announced Phase III ABSSSI trials in H2 2017.
Graham Lumsden, CEO, stated: “This is a major milestone for Motif given the complexity and costs usually associated with the manufacture of clinical trial supplies in sufficient quantity for large Phase III trials. We were able to utilise commercial-scale batches of the API (Active Pharmaceutical Ingredient) that we own as a result of our merger earlier this year with Nuprim Inc. This API, which we reprocessed to generate new material, has now been used to manufacture sterile ampoules for clinical trial supplies and we are on track to complete the trials in the second half 2017.”